newsfilter
← Latest News
GlobeNewswire·

Chemed Reports Third-Quarter 2026 Results

CHE
  • Chemed Corporation reported third-quarter 2026 consolidated revenue of $690.9 million, an increase of 10.6% compared to the prior year.
  • GAAP diluted EPS reached $5.45, up 22.2%, while adjusted diluted EPS was $6.75, an increase of 28.1%.
  • VITAS segment net patient revenue grew 12.2% to $457.4 million, driven by a 9.4% rise in average daily census to 24,428.
  • VITAS admissions increased 7.2% to 18,995, with net income excluding discrete items rising 44.7% to $70.8 million.
  • VITAS adjusted EBITDA excluding the Medicare Cap increased 31.4% to $92.5 million, resulting in a margin of 20.2%.
  • VITAS accrued $828,000 in Medicare Cap billing limitations for the quarter, a significant decrease from the $6.1 million recorded in the same period of 2025.
  • Roto-Rooter segment revenue grew 7.5% to $233.5 million, with commercial revenue up 9.0% and residential revenue up 5.2%.
  • Roto-Rooter net income excluding discrete items declined 1.8% to $33.3 million, and adjusted EBITDA fell 2.5% to $48.2 million.
  • Roto-Rooter adjusted EBITDA margin decreased 213 basis points to 20.6%, impacted by a 17.1% increase in selling, general, and administrative expenses.
  • Roto-Rooter re-acquired multiple franchise territories in California for approximately $62.5 million, encompassing a population of over 12 million people.
  • Chemed held $48.4 million in cash equivalents and $236.0 million in long-term debt as of September 30, 2026.
  • The company repurchased 125,000 shares for $66.0 million during the quarter, leaving approximately $73.7 million in remaining share repurchase authorization.
  • Chemed updated its full-year 2026 adjusted EPS guidance to indicate results will be at or slightly above the high-end of previous expectations.
  • A conference call to discuss these results is scheduled for October 28, 2026, at 10 a.m. ET.